Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
Aurora
13123 East 16th Ave Aurora, CO 80045

720-777-1234

Livia Veress, MD

Pediatric Pulmonology

Board Certified

Locations

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045

720-777-1234

Get directions

Provider Expertise

Clinical Interest for Patients

My many clinical interests include Bronchopulmonary Dysplasia, Airway Anatomical DIsorders, Congenital Lung Disorders, Plastic Bronchitis, Bronchiolitis Obliterans, Pulmonary Fibrosis, Congenital Heart Disease-Associated Lung Abnormalities, ARDS


Care Philosophy

I strive to provide an extremely thorough care for all my patients. I believe in treating the person as a whole, taking every aspect of a patient’s body and health into consideration during diagnosis and treatment.


Specialties

  • Pediatrics ( 2005 )
  • Pediatric Critical Care Medicine
  • Pediatric Pulmonology ( 2010 )

Conditions & Treatments

  • Lungs and Breathing

    Asthma, Chronic Lung Disease of Prematurity (Bronchopulmonary Dysplasia), Chronic Mechanical Ventilation, Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Cystic Fibrosis, Granulomatous Lung Disease, Interstitial Lung Disease, Interventional Pulmonology, Lung Development, Lung Disease, Neonatal Lung Diseases, Obstructive Sleep Apnea, Pulmonary Disorders, Pulmonary Embolism, Pulmonary Hypertension, Respiratory Disease, Tracheostomy Dependence

  • Critical Care

    Long COVID

  • Dry Skin

Education & Training

Medical Schools

MD, Louisiana State University School of Medicine in New Orleans (2002)


Undergraduate Schools

BS, Tulane University (LA) (1996)


Residency Program

Louisiana State University Program (2005)


Fellowships

University of Colorado (2006)

University of Colorado (2010)

Professional Memberships

American Academy of Pediatrics (AAP), Resident Fellow


American Medical Association, Member


American Thoracic Society (ATS), Member


EAPCCT, Member


SOT, Full Member


Research & Grants

Grants

Advanced Development of Alteplase as a Medical Countermeasure for Pulmonary Injury Associated with Sulfur Mustard Inhalation - Proof of Concept in a Swine Model (2015)

U54: Project 2. Development of antidotes for toxic gases (2016)

U01: Anticholinergic and Antiepileptic Therapies for Chlorine Toxicity (2018)

Alteplase for Sulfur Mustard Gas (SMG) Inhalation (2019)

R01: Vascular Injury and Repair Predict Divergent Late Onset Cardiovascular Morbidities After Chlorine and Sulfur Mustard Exposure (2023)


Research Interests for Patients

Translational research, acute lung injury/acute respiratory distress syndrome, bronchiolitis obliterans, interstitial lung fibrosis, pulmonary wound repair and tissue regeneration, chemical inhalation injury, airway coagulation, fibrinolytic and antifibrotic drug therapies, drug development, plastic bronchitis, pulmonary hypertension, pulmonary vascular thrombosis, endothelialitis, microvascular thrombosis, immunothrombosis, severe COVID-19 illness, lung growth abnormalities after in utero environmental exposures, cardiac dysfunction, septic shock, aspiration-induced injury and other pulmonary toxicology.

information for referring providers

Referral Contact Phone

(720) 777-6181

Clinical Interests for Referring Providers

My many clinical interests include Bronchopulmonary Dysplasia, Airway Anatomical DIsorders, Congenital Lung Disorders, Plastic Bronchitis, Bronchiolitis Obliterans, Pulmonary Fibrosis, Congenital Heart Disease-Associated Lung Abnormalities, ARDS

Research Interest for Referring Providers

Translational research, acute lung injury/acute respiratory distress syndrome, bronchiolitis obliterans, interstitial lung fibrosis, pulmonary wound repair and tissue regeneration, chemical inhalation injury, airway coagulation, fibrinolytic and antifibrotic drug therapies, drug development, plastic bronchitis, pulmonary hypertension, pulmonary vascular thrombosis, endothelialitis, microvascular thrombosis, immunothrombosis, severe COVID-19 illness, lung growth abnormalities after in utero environmental exposures, cardiac dysfunction, septic shock, aspiration-induced injury and other pulmonary toxicology.